Karo Pharma is a leading specialty pharmaceutical company in the Nordics. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.
Karo Pharma was founded in 1987 and has been listed on Nasdaq Stockholm since 1998. In 2014 the company’s strategic direction was changed, with the intention of becoming an international specialty pharma company with solid growth and profitability, that contributes to improved health and quality of life. The Company has a strong position in the Nordic region and has taken a first step to establish a European presence through historical acquisitions. The Company is currently in stable growth with healthy profitability through sales of established brands, which are generating positive cash flows.
To Karo Pharma
Market trends and drivers
The large specialty pharmaceutical market demonstrates stable growth over the cycles and high resilience during economic downturns. The market offers attractive growth opportunities, both organically driven by underlying patient-critical demand, and inorganically through a generally high M&A activity as a result of the continued consolidation in the pharmaceutical industry.
The strategic direction of the company builds on the journey Karo Pharma has already started. EQT intends to support Karo Pharma through continued long term investments in Karo Pharma’s product portfolio and strengthening of the Company’s go to market capabilities. By providing financial and strategic resources, EQT can support an accelerated development of Karo Pharma’s business organically and through synergetic add on acquisitions in new and existing markets.
The icons illustrate the portfolio companies' positive societal contributions based on their solutions i.e. how their products and/or services solve key challenges expressed as the Sustainable Development Goals (SDGs)